Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group.
about
HPV & head and neck cancer: a descriptive updateInterventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapyMolecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitorsAdvanced oropharyngeal squamous cell carcinoma: Pathogenesis, treatment, and novel therapeutic approachesWhat is the best treatment for patients with human papillomavirus-positive and -negative oropharyngeal cancer?Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials.An update on larynx cancerAnticancer Activity of Apaziquone in Oral Cancer Cells and Xenograft Model: Implications for Oral Cancer TherapyErlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II studyPhase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.Modified docetaxel, cisplatin and fluorouracil therapy as the first-line treatment for patients with recurrent/metastatic squamous cell carcinoma of the head and neck cancer: a retrospective study.Rapid palliation of symptoms with platinum-based chemotherapy plus cetuximab in recurrent oral cancer: a case report.Multicenter randomized phase 2 clinical trial of a recombinant human endostatin adenovirus in patients with advanced head and neck carcinomaNuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinomaFeasibility of cisplatin/5-fluorouracil and panitumumab in Japanese patients with squamous cell carcinoma of the head and neck.Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapyAn effective and well-tolerated strategy in recurrent and/or metastatic head and neck cancer: successive lines of active chemotherapeutic agents.Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618.The diagnosis and treatment of oral cavity cancer.Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro.The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal.Cetuximab concomitant with second-line radiation therapy in patients with locally advanced recurrent squamous cell head and neck cancer.Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part.Activity of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid against human head and neck carcinoma xenograftsEmerging drugs to treat squamous cell carcinomas of the head and neck.Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum C₁₈-ceramide as a novel biomarker for monitoring response.ZEB1 transcriptionally regulated carbonic anhydrase 9 mediates the chemoresistance of tongue cancer via maintaining intracellular pH.A new finite element approach for near real-time simulation of light propagation in locally advanced head and neck tumorsInduction chemotherapy with paclitaxel and cisplatin to concurrent radiotherapy and weekly paclitaxel in the treatment of loco-regionally advanced, stage IV (M0), head and neck squamous cell carcinoma. Mature results of a prospective studyA phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck.The role of chemotherapy in the management of patients with head and neck cancer.Prognostic Factors of Primary Intraosseous Squamous Cell Carcinoma (PIOSCC): A Retrospective ReviewMitochondrial fission determines cisplatin sensitivity in tongue squamous cell carcinoma through the BRCA1-miR-593-5p-MFF axis.Outcomes of salvage surgery with free flap reconstruction for recurrent oral and oropharyngeal cancerPhase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab®-Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma.0-7-21 hypofractionated palliative radiotherapy: an effective treatment for advanced head and neck cancers.The 14-3-3σ/GSK3β/β-catenin/ZEB1 regulatory loop modulates chemo-sensitivity in human tongue cancerNew approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN).Taxanes in head and neck cancer.Systemic therapy strategies for head-neck carcinomas: Current status
P2860
Q21198763-6BDD50A7-0B4C-4DF5-83CF-349498C41989Q24235245-10AFD705-D3B0-483C-99B4-4DEEA13A63B9Q26750719-5FB563BE-0540-4344-89C9-3003FC289D25Q26767046-D65D1956-1351-4661-AE31-E937C90E197BQ27026269-6B433FAB-A81C-4EA2-8BA1-CEFF01B6FD62Q27853003-6C762353-7659-4218-A882-2F26652DD8F3Q28079132-BC4B0CF5-D343-4593-85CE-C9232198DF68Q28546757-B0753890-4566-4184-98A9-11F369BB0FEAQ33406802-FE58570B-6C00-4ACC-BE48-50503858BAFAQ33434648-61D65129-21F0-4643-B81A-182630EB33E7Q33436548-94E608CD-A279-4433-9A99-F910C4920378Q33706132-1F5CD20A-0267-4E2F-8A61-AAC0A0852E50Q33724272-D37D9202-D72D-4C2D-AC83-6A818781EDF9Q33751186-42601755-E063-450C-89F3-55BFC0F1FBA0Q33807021-38DB0012-5EED-4CBE-A0A9-8918136F4507Q33839177-DC015A90-A467-47E5-9335-21CCBD9CA7F1Q33895284-645A5930-0EF8-435C-A7EE-DFE3AF7C1ED5Q33941497-31947C82-59BF-482B-8E2A-E2519182D96FQ34646602-B073C283-AA46-4A20-9095-8A9B47FC8566Q34781075-906053ED-EB0A-41A4-A942-34A5FE3C0B2CQ34957320-B1B163EC-9BC1-42A8-966E-527CFCF2B079Q34999913-151CAF1A-824F-4937-AA0B-5667993D0E3FQ35034608-C1078C5C-97E6-473B-9E10-1A336A96DEF3Q35082693-2A474201-FF58-4EE3-9ADC-7AEA83F591D6Q35098322-6133D126-D3B0-4374-8CDF-8EEF0C27AB5FQ35223807-E2EC3574-40B8-4CCF-B6DB-FA9CAECF8031Q35497226-4E741987-4CFC-4623-A633-514202730D99Q35537960-2396CB92-D82C-43E6-91E8-385723E6CC06Q35605411-68249E19-B8C2-4F85-8BAB-911ACD6E38CAQ35743883-B38BB67B-5BD0-4ACA-80EA-4EBCDBADA8C5Q35882999-C39F0732-FA1A-4E3D-BFA0-ED474C97F24CQ35988635-87FFE8F7-3F4E-4359-8564-9047E6A04E49Q36020872-D38B32CF-84E7-4806-9DF9-031BD928B4C2Q36076382-5518C1BC-262B-4321-A728-4DC050239B06Q36076485-BD90D09C-01A4-4010-B7D5-70C89074E596Q36235509-C1585F7C-B7C8-4A0D-BF1E-0177AA4948C1Q36299623-F6349A5E-1E4A-470A-9FD4-ADECBA6EF0EBQ36303845-3970628B-A2D5-42D8-AF7C-9009923D22B3Q36429649-62FD2F69-0397-4539-9711-0195ACED9492Q36529843-D29BBC58-97C0-45B3-9638-375D76029845
P2860
Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Randomized phase III evaluatio ...... rn Cooperative Oncology Group.
@ast
Randomized phase III evaluatio ...... rn Cooperative Oncology Group.
@en
type
label
Randomized phase III evaluatio ...... rn Cooperative Oncology Group.
@ast
Randomized phase III evaluatio ...... rn Cooperative Oncology Group.
@en
prefLabel
Randomized phase III evaluatio ...... rn Cooperative Oncology Group.
@ast
Randomized phase III evaluatio ...... rn Cooperative Oncology Group.
@en
P2093
P356
P1476
Randomized phase III evaluatio ...... rn Cooperative Oncology Group.
@en
P2093
Arlene A Forastiere
Barbara Murphy
John Ensley
Maha H A Hussain
Michael K Gibson
Ronald C DeConti
P304
P356
10.1200/JCO.2005.01.057
P407
P577
2005-05-01T00:00:00Z